Raymond James & Associates’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $111M | Buy |
1,327,349
+175,294
| +15% | +$13.8M | 0.07% | 246 |
|
|
2024
Q2 | $88.7M | Sell |
1,152,055
-12,648
| -1% | -$926K | 0.06% | 281 |
|
|
2024
Q1 | $79.8M | Sell |
1,164,703
-16,871
| -1% | -$1.08M | 0.05% | 302 |
|
|
2023
Q4 | $68.3M | Buy |
1,181,574
+44,000
| +4% | +$2.35M | 0.05% | 311 |
|
|
2023
Q3 | $60.1M | Sell |
1,137,574
-27,389
| -2% | -$1.44M | 0.05% | 311 |
|
|
2023
Q2 | $63M | Sell |
1,164,963
-150,578
| -11% | -$7.86M | 0.05% | 308 |
|
|
2023
Q1 | $65.8M | Sell |
1,315,541
-37,792
| -3% | -$1.78M | 0.06% | 292 |
|
|
2022
Q4 | $62.6M | Buy |
1,353,333
+117,602
| +10% | +$5.09M | 0.06% | 293 |
|
|
2022
Q3 | $47.9M | Sell |
1,235,731
-575,643
| -32% | -$23.1M | 0.05% | 328 |
|
|
2022
Q2 | $67.5M | Sell |
1,811,374
-59,914
| -3% | -$2.44M | 0.07% | 260 |
|
|
2022
Q1 | $82.9M | Sell |
1,871,288
-310,350
| -14% | -$13.4M | 0.07% | 241 |
|
|
2021
Q4 | $92.7M | Sell |
2,181,638
-224,583
| -9% | -$9.44M | 0.07% | 230 |
|
|
2021
Q3 | $104M | Buy |
2,406,221
+61,808
| +3% | +$2.73M | 0.09% | 197 |
|
|
2021
Q2 | $100M | Buy |
2,344,413
+334,503
| +17% | +$14.1M | 0.09% | 195 |
|
|
2021
Q1 | $77.7M | Buy |
2,009,910
+423,096
| +27% | +$16M | 0.08% | 221 |
|
|
2020
Q4 | $57M | Buy |
1,586,814
+352,727
| +29% | +$12.7M | 0.06% | 258 |
|
|
2020
Q3 | $47.2M | Buy |
1,234,087
+85,025
| +7% | +$3.28M | 0.06% | 272 |
|
|
2020
Q2 | $40.3M | Buy |
1,149,062
+90,842
| +9% | +$3.27M | 0.05% | 290 |
|
|
2020
Q1 | $34.5M | Buy |
1,058,220
+89,354
| +9% | +$3.49M | 0.05% | 286 |
|
|
2019
Q4 | $43.8M | Buy |
968,866
+129,201
| +15% | +$5.41M | 0.06% | 302 |
|
|
2019
Q3 | $34.2M | Buy |
839,665
+103,915
| +14% | +$4.4M | 0.05% | 356 |
|
|
2019
Q2 | $31.6M | Buy |
735,750
+40,874
| +6% | +$1.57M | 0.05% | 385 |
|
|
2019
Q1 | $26.7M | Buy |
694,876
+75,571
| +12% | +$2.89M | 0.04% | 423 |
|
|
2018
Q4 | $21.9M | Buy |
619,305
+102,169
| +20% | +$3.71M | 0.04% | 440 |
|
|
2018
Q3 | $19.9M | Buy |
517,136
+43,734
| +9% | +$1.53M | 0.03% | 532 |
|
|
2018
Q2 | $15.5M | Sell |
473,402
-17,802
| -4% | -$537K | 0.03% | 618 |
|
|
2018
Q1 | $13.4M | Sell |
491,204
-129,791
| -21% | -$3.53M | 0.02% | 633 |
|
|
2017
Q4 | $15.4M | Sell |
620,995
-23,353
| -4% | -$644K | 0.03% | 570 |
|
|
2017
Q3 | $18.8M | Buy |
644,348
+29,440
| +5% | +$813K | 0.04% | 480 |
|
|
2017
Q2 | $17M | Buy |
614,908
+38,211
| +7% | +$1.01M | 0.04% | 488 |
|
|
2017
Q1 | $14.3M | Sell |
576,697
-86,846
| -13% | -$2.11M | 0.03% | 521 |
|
|
2016
Q4 | $14.4M | Buy |
663,543
+26,631
| +4% | +$581K | 0.04% | 487 |
|
|
2016
Q3 | $15.2M | Buy |
636,912
+16,560
| +3% | +$395K | 0.04% | 447 |
|
|
2016
Q2 | $14.5M | Buy |
620,352
+143,017
| +30% | +$3.09M | 0.05% | 412 |
|
|
2016
Q1 | $8.98M | Sell |
477,335
-3,314
| -0.7% | -$58.2K | 0.03% | 563 |
|
|
2015
Q4 | $8.86M | Buy |
480,649
+168,348
| +54% | +$3.02M | 0.03% | 559 |
|
|
2015
Q3 | $5.13M | Buy |
312,301
+67,581
| +28% | +$1.16M | 0.02% | 742 |
|
|
2015
Q2 | $4.33M | Buy |
244,720
+24,599
| +11% | +$440K | 0.02% | 882 |
|
|
2015
Q1 | $3.91M | Buy |
220,121
+47,204
| +27% | +$746K | 0.02% | 870 |
|
|
2014
Q4 | $2.29M | Buy |
172,917
+18,359
| +12% | +$235K | 0.01% | 1081 |
|
|
2014
Q3 | $1.82M | Sell |
154,558
-26,486
| -15% | -$334K | 0.01% | 1148 |
|
|
2014
Q2 | $2.31M | Buy |
181,044
+17,742
| +11% | +$231K | 0.01% | 1019 |
|
|
2014
Q1 | $2.21M | Buy |
163,302
+17,475
| +12% | +$229K | 0.02% | 974 |
|
|
2013
Q4 | $1.75M | Buy |
145,827
+117,982
| +424% | +$1.39M | 0.01% | 1034 |
|
|
2013
Q3 | $327K | Sell |
27,845
-11,370
| -29% | -$123K | ﹤0.01% | 1753 |
|
|
2013
Q2 | $364K | Buy |
+39,215
| New | +$333K | ﹤0.01% | 1649 |
|
Other funds holding BSX
Raymond James & Associates's BSX Position: Q3 2024 in Review
Raymond James & Associates increased its Boston Scientific (BSX) stake by 15% in Q3 2024, buying an estimated $13.8M and bringing the position to 1,327,349 shares worth $111M. The position accounts for 0.07% of the portfolio, ranked #246.
Raymond James & Associates first reported a position in BSX in Q2 2013 and has held it in 46 quarters since. 1,396 funds tracked by Wall St. Rank hold BSX as of Q3 2024.
- Raymond James & Associates held 1,327,349 shares of Boston Scientific worth $111M as of Q3 2024.
- Raymond James & Associates bought 175,294 Boston Scientific shares in Q3 2024, an estimated $13.8M.
- Boston Scientific made up 0.07% of Raymond James & Associates's portfolio in Q3 2024, its #246 holding.
- Raymond James & Associates first reported a position in Boston Scientific in Q2 2013 and has held it in 46 quarters since.
- 1,396 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.